Neurology
Opinion
The power and promise of person-generated health data (Part II)
While PGHD has the potential to help people, it also presents new challenges.
Conference Coverage
Targeting gut bacteria may improve levodopa uptake
Differences in metabolism of levodopa between patients with Parkinson’s disease may be caused by variations in abundance of the gut bacteria ...
Feature
Elderly Americans carry heavier opioid burden
Those over age 65 years fill prescriptions for twice the amount, compared with younger adults.
Latest News
Due to the COVID-19 pandemic, the AAN urges feds to further expand telehealth benefits
According to the AAN, the easing of restrictions on telehealth should be extended beyond Medicare fee-for-service to both Medicare Advantage and...
Feature
New ASAM guideline released amid COVID-19 concerns
During the COVID-19 pandemic, “it is especially important” for clinicians to ensure that individuals with OUD continue to receive evidence-based...
Latest News
Scientific community ‘shocked’ by loss of MIND diet pioneer
Martha Clare Morris, ScD, a pioneer in research linking nutrition to brain health and a creator of the breakthrough MIND diet, has died of cancer...
Cases That Test Your Skills
Depression, or something else?
Ms. A, age 60, presents with severe headaches and depression, including a suicide attempt. She’s also been repeatedly sorting through her...
Conference Coverage
Depression in MS predicted worsening of neurologic function
WEST PALM BEACH, FLA. – Researchers hypothesize that the association may relate to depression’s influence on psychomotor function.
FDA/CDC
FDA OKs first orally disintegrating agent for rapid migraine relief
This is the first CGRP receptor antagonist available in a fast-acting orally disintegrating tablet for the acute treatment of migraine in adults...
News
USPSTF again deems evidence insufficient to recommend cognitive impairment screening in older adults
The USPSTF reaffirmed its 2014 statement by concluding that current evidence is insufficient to make a recommendation about screening for...
FDA/CDC
FDA approves first IV migraine prevention drug
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine...